Clinical Utility of Sero-Immunological Responses Against SARS-CoV-2Nucleocapsid Protein During Subsequent Prevalence of Wild-Type, Delta Variant, and Omicron Variant
Beomki LEE; Jae-Hoon KO; Jin-Yang BAEK; Haein KIM; Kyungmin HUH; Sun-Young CHO; Cheol-In KANG; Doo-Ryeon CHUNG; Kyong-Ran PECK; Eun-Suk KANG.
Artículo
en Inglés
| WPRIM | ID: wpr-1001237